Last week, Optimum hosted its 17th Annual Healthcare Investor Conference 2025. Held in the heart of London, the event brought together a powerhouse of industry leaders, investors, innovators, and communicators to exchange ideas, explore the market outlook, and tackle the pressing questions facing the life sciences sector. If you missed the day, or just want […]
Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]
– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis – Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis Edinburgh and London, UK, 9 October […]
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday […]
